Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

2.40
+0.04001.69%
Pre-market: 2.410.0100+0.42%08:05 EDT
Volume:2.03M
Turnover:4.85M
Market Cap:432.21M
PE:-5.94
High:2.45
Open:2.39
Low:2.33
Close:2.36
52wk High:6.88
52wk Low:1.61
Shares:180.09M
Float Shares:132.00M
Volume Ratio:0.80
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4039
EPS(LYR):-0.4216
ROE:-56.66%
ROA:-33.03%
PB:2.60
PE(LYR):-5.69

Loading ...

Wedbush Lowers Compass Therapeutics Price Target to $5 From $8, Maintains Outperform Rating

MT Newswires Live
·
Apr 27

Compass Therapeutics Shares Down 63% at $1.84 After Cancer Drug Fails Overall Survival Trial Goal

THOMSON REUTERS
·
Apr 27

Compass Therapeutics Inc. Shares Down 72.2% at $1.40 in Premarket Trade After Trial Results for Tovecimig

THOMSON REUTERS
·
Apr 27

Compass Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 27

BRIEF-Compass Therapeutics Inc. Tovecimig Plus Paclitaxel Improves Median Pfs To 4.7 Months Versus 2.6 Months

Reuters
·
Apr 27

Top Premarket Decliners

MT Newswires Live
·
Apr 27

Compass Therapeutics Bile Cancer Treatment Doesn't Meet Overall Survival Goal

Dow Jones
·
Apr 27

Compass says tovecimig plus paclitaxel extends PFS in biliary tract cancer trial

Reuters
·
Apr 27

Compass Therapeutics Inc. - Tovecimig Plus Paclitaxel Improves Median Pfs to 4.7 Months VS 2.6 Months

THOMSON REUTERS
·
Apr 27

Tovecimig Demonstrates Statistically Significant Benefit in Companion-002 Randomized Phase 2/3 Study in Patients With Biliary Tract Cancer

THOMSON REUTERS
·
Apr 27

Compass Therapeutics Inc.: Met Key Secondary Endpoint of Pfs and Showed Additional Compelling Results in Randomized Companion-002 Study

THOMSON REUTERS
·
Apr 27

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM

Reuters
·
Apr 27

Compass Therapeutics Shares Gain Ahead of Trial Data for Biliary Tract Cancer Drug

Dow Jones
·
Apr 25

Compass Therapeutics to report COMPANION-002 secondary endpoints for tovecimig in biliary cancer

Reuters
·
Apr 25

Compass Therapeutics (CMPX): Favorable Risk‑Reward Ahead of Pivotal Tovecimig Data in Biliary Tract Cancer

TIPRANKS
·
Apr 07

Buy Rating on Compass Therapeutics: Anticipating Pivotal Tovecimig Data as a Key Value Inflection Point in Advanced Biliary Tract Cancer

TIPRANKS
·
Mar 31

Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Maze Therapeutics, Inc. (MAZE) and Compass Therapeutics (CMPX)

TIPRANKS
·
Mar 26

Compass Therapeutics Price Target Maintained With a $12.00/Share by Guggenheim

Dow Jones
·
Mar 24

Compass Therapeutics (CMPX) Receives a Buy from Guggenheim

TIPRANKS
·
Mar 24

Analysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (SLN), RxSight (RXST) and Compass Therapeutics (CMPX)

TIPRANKS
·
Mar 06